(Q30433670)

English

Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

11 November 2017

1 reference

based on heuristic

inferred from title

Phase II clinical trial of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant ovarian or primary peritoneal cancer: a gynecologic oncology group study (English)

1 reference

Europe PubMed Central

11 November 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

gynecologic oncology

1 reference

based on heuristic

inferred from title

Carolyn Y. Muller

8

object named as

Carolyn Y Muller

0 references

Daniela E. Matei

7

object named as

Daniela Matei

1 reference

Europe PubMed Central

11 November 2017

Bradley J. Monk

5

object named as

Bradley J Monk

1 reference

Europe PubMed Central

11 November 2017

author name string

Koen De Geest

1

1 reference

Europe PubMed Central

11 November 2017

John A Blessing

2

1 reference

Europe PubMed Central

11 November 2017

Robert T Morris

3

1 reference

Europe PubMed Central

11 November 2017

S Diane Yamada

4

1 reference

Europe PubMed Central

11 November 2017

Susan L Zweizig

6

1 reference

Europe PubMed Central

11 November 2017

William E Richards

9

1 reference

Europe PubMed Central

11 November 2017

language of work or name

0 references

publication date

16 November 2009

1 reference

Europe PubMed Central

11 November 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

11 November 2017

28

1 reference

Europe PubMed Central

11 November 2017

1

1 reference

Europe PubMed Central

11 November 2017

149-153

1 reference

Europe PubMed Central

11 November 2017

Novel neurosensory testing in cancer patients treated with the epothilone B analog, ixabepilone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Evidence for microtubule target engagement in tumors of patients receiving ixabepilone

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Class III beta-tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Chromosomal instability, colorectal cancer and taxane resistance

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Epothilones: mechanism of action and biologic activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Dependence of paclitaxel sensitivity on a functional spindle assembly checkpoint

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Do beta-tubulin mutations have a role in resistance to chemotherapy?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Novel molecules that interact with microtubules and have functional activity similar to Taxol

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

20 June 2018

Phase II genomics study of ixabepilone as neoadjuvant treatment for breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

The effect of ketoconazole on the pharmacokinetics and pharmacodynamics of ixabepilone: a first in class epothilone B analogue in late-phase clinical development.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

Phase I dose escalation study of weekly ixabepilone, an epothilone analog, in patients with advanced solid tumors who have failed standard therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

Epothilones and new analogues of the microtubule modulators in taxane-resistant disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

A phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

Optimal flexible designs in phase II clinical trials.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

Activities of the microtubule-stabilizing agents epothilones A and B with purified tubulin and in cells resistant to paclitaxel (Taxol(R)).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2799230

26 November 2018

Phase II clinical trial of the epothilone B analog, ixabepilone, in patients with non small-cell lung cancer whose tumors have failed first-line platinum-based chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

New tubulin targeting agents currently in clinical development

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/19917861

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2009.24.1455

1 reference

Europe PubMed Central

11 November 2017

1 reference

Europe PubMed Central

11 November 2017

1 reference

Europe PubMed Central

11 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30433670&oldid=2032769396"